Cargando…
Population Pharmacokinetics of CC-122
BACKGROUND: CC-122 is a cereblon-modulating agent that exerts direct cell-autonomous activity against malignant B cells and immunomodulatory effects. Herein, a population pharmacokinetic (popPK) model of CC-122 was developed and the influence of demographic and disease-related covariates on populati...
Autores principales: | Cheng, Yiming, Chen, Jian, Pourdehnad, Michael, Zhou, Simon, Li, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093142/ https://www.ncbi.nlm.nih.gov/pubmed/33958900 http://dx.doi.org/10.2147/CPAA.S310604 |
Ejemplares similares
-
Exposure-response analysis to assess the concentration–QTc relationship of CC-122
por: Li, Yan, et al.
Publicado: (2016) -
Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma
por: Ribrag, Vincent, et al.
Publicado: (2022) -
Drug‐Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC‐122) in Healthy Adult Subjects
por: Ogasawara, Ken, et al.
Publicado: (2019) -
Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022) -
High-resolution structures of the bound effectors avadomide (CC-122) and iberdomide (CC-220) highlight advantages and limitations of the MsCI4 soaking system
por: Heim, Christopher, et al.
Publicado: (2022)